Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Comparing low-pass sequencing and genotyping for trait mapping in pharmacogenetics

Kaja Wasik, Tomaz Berisa, Joseph K. Pickrell, Jeremiah H. Li, Dana J. Fraser, Karen King, Charles Cox
doi: https://doi.org/10.1101/632141
Kaja Wasik
Gencove, Inc. New York, NY 10016
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomaz Berisa
Gencove, Inc. New York, NY 10016
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph K. Pickrell
Gencove, Inc. New York, NY 10016
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: joe@gencove.com charles.j.cox@gsk.com
Jeremiah H. Li
Gencove, Inc. New York, NY 10016
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dana J. Fraser
PAREXEL Genomic Medicine, Durham, NC, USA, 27713
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen King
PAREXEL Genomic Medicine, Durham, NC, USA, 27713
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles Cox
GlaxoSmithKline, Stevenage, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: joe@gencove.com charles.j.cox@gsk.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

Abstract

Low pass sequencing has been proposed as a cost-effective alternative to genotyping arrays to identify genetic variants that influence multifactorial traits in humans. For common diseases this typically has required both large sample sizes and comprehensive variant discovery. Genotyping arrays are also routinely used to perform pharmacogenetic (PGx) experiments where sample sizes are likely to be significantly smaller, but clinically relevant effect sizes likely to be larger. To assess how low pass sequencing would compare to array based genotyping for PGx we compared a low-pass assay (in which 1× coverage or less of a target genome is sequenced) along with software for genotype imputation to standard approaches. We sequenced 79 individuals to 1× genome coverage and genotyped the same samples on the Affymetrix Axiom Biobank Precision Medicine Research Array (PMRA). We then down-sampled the sequencing data to 0.8×, 0.6×, and 0.4× coverage, and performed imputation. Both the genotype data and the sequencing data were further used to impute human leukocyte antigen (HLA) genotypes for all samples. We compared the sequencing data and the genotyping array data in terms of four metrics: overall concordance, concordance at single nucleotide polymorphisms in pharmacogenetics-related genes, concordance in imputed HLA genotypes, and imputation r2. Overall concordance between the two assays ranged from 98.2% (for 0.4× coverage sequencing) to 99.2% (for 1× coverage sequencing), with qualitatively similar numbers for the subsets of variants most important in pharmacogenetics. At common single nucleotide polymorphisms (SNPs), the mean imputation r2 from the genotyping array was 90%, which was comparable to the imputation r2 from 0.4× coverage sequencing, while the mean imputation r2 from 1× sequencing data was 96%. These results indicate that low-pass sequencing to a depth above 0.4× coverage attains higher power for trait mapping when compared to the PMRA.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 08, 2019.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Comparing low-pass sequencing and genotyping for trait mapping in pharmacogenetics
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
Share
Comparing low-pass sequencing and genotyping for trait mapping in pharmacogenetics
Kaja Wasik, Tomaz Berisa, Joseph K. Pickrell, Jeremiah H. Li, Dana J. Fraser, Karen King, Charles Cox
bioRxiv 632141; doi: https://doi.org/10.1101/632141
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Comparing low-pass sequencing and genotyping for trait mapping in pharmacogenetics
Kaja Wasik, Tomaz Berisa, Joseph K. Pickrell, Jeremiah H. Li, Dana J. Fraser, Karen King, Charles Cox
bioRxiv 632141; doi: https://doi.org/10.1101/632141

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetics
Subject Areas
All Articles
  • Animal Behavior and Cognition (1530)
  • Biochemistry (2488)
  • Bioengineering (1745)
  • Bioinformatics (9696)
  • Biophysics (3912)
  • Cancer Biology (2976)
  • Cell Biology (4210)
  • Clinical Trials (135)
  • Developmental Biology (2636)
  • Ecology (4107)
  • Epidemiology (2033)
  • Evolutionary Biology (6906)
  • Genetics (5217)
  • Genomics (6516)
  • Immunology (2191)
  • Microbiology (6967)
  • Molecular Biology (2763)
  • Neuroscience (17334)
  • Paleontology (126)
  • Pathology (430)
  • Pharmacology and Toxicology (708)
  • Physiology (1061)
  • Plant Biology (2496)
  • Scientific Communication and Education (646)
  • Synthetic Biology (832)
  • Systems Biology (2690)
  • Zoology (432)